William Blair & Company
DGX icon

William Blair & Company’s Quest Diagnostics DGX Stock Holding History

William Blair & Company’s Portfolio DGX Stock Details DGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$18M Sell
91,972
-11,403
-11% -$2.22M 0.05% 257
2025
Q4 		$17.9M Buy
103,375
+5,457
+6% +$994K 0.05% 252
2025
Q3 		$18.7M Buy
97,918
+6,709
+7% +$1.19M 0.05% 240
2025
Q2 		$16.4M Buy
91,209
+38,588
+73% +$6.7M 0.05% 257
2025
Q1 		$8.9M Buy
52,621
+12,464
+31% +$2.05M 0.03% 353
2024
Q4 		$6.06M Buy
40,157
+5,218
+15% +$812K 0.02% 446
2024
Q3 		$5.42M Buy
34,939
+24,385
+231% +$3.64M 0.02% 486
2024
Q2 		$1.44M Buy
10,554
+6
+0.1% +$822 ﹤0.01% 772
2024
Q1 		$1.4M Sell
10,548
-98
-0.9% -$12.7K ﹤0.01% 776
2023
Q4 		$1.47M Sell
10,646
-739
-6% -$97.2K 0.01% 747
2023
Q3 		$1.39M Sell
11,385
-3,100
-21% -$413K 0.01% 749
2023
Q2 		$2.04M Buy
14,485
+173
+1% +$23.8K 0.01% 660
2023
Q1 		$2.02M Buy
14,312
+5,578
+64% +$798K 0.01% 652
2022
Q4 		$1.37M Buy
8,734
+477
+6% +$68.5K 0.01% 735
2022
Q3 		$1.01M Buy
8,257
+98
+1% +$12.9K ﹤0.01% 810
2022
Q2 		$1.08M Sell
8,159
-13
-0.2% -$1.77K ﹤0.01% 822
2022
Q1 		$1.12M Sell
8,172
-8,488
-51% -$1.18M ﹤0.01% 880
2021
Q4 		$2.88M Buy
16,660
+3,002
+22% +$457K 0.01% 627
2021
Q3 		$1.99M Sell
13,658
-935
-6% -$137K 0.01% 708
2021
Q2 		$1.93M Buy
14,593
+2,289
+19% +$300K 0.01% 716
2021
Q1 		$1.58M Sell
12,304
-19,037
-61% -$2.35M 0.01% 759
2020
Q4 		$3.73M Buy
31,341
+1,532
+5% +$187K 0.01% 498
2020
Q3 		$3.41M Buy
29,809
+17,281
+138% +$2.04M 0.01% 472
2020
Q2 		$1.43M Buy
12,528
+7,973
+175% +$846K 0.01% 638
2020
Q1 		$366K Sell
4,555
-865
-16% -$89.6K ﹤0.01% 957
2019
Q4 		$579K Buy
5,420
+120
+2% +$12.5K ﹤0.01% 943
2019
Q3 		$567K Hold
5,300
– – ﹤0.01% 909
2019
Q2 		$540K Buy
5,300
+1,022
+24% +$98.2K ﹤0.01% 951
2019
Q1 		$385K Sell
4,278
-186
-4% -$16.1K ﹤0.01% 1049
2018
Q4 		$372K Buy
4,464
+289
+7% +$27.1K ﹤0.01% 1007
2018
Q3 		$451K Hold
4,175
– – ﹤0.01% 990
2018
Q2 		$459K Hold
4,175
– – ﹤0.01% 977
2018
Q1 		$419K Sell
4,175
-162
-4% -$16.6K ﹤0.01% 974
2017
Q4 		$427K Sell
4,337
-396
-8% -$37.5K ﹤0.01% 1015
2017
Q3 		$443K Buy
4,733
+907
+24% +$96.3K ﹤0.01% 969
2017
Q2 		$425K Buy
3,826
+1,425
+59% +$151K ﹤0.01% 1037
2017
Q1 		$234K Buy
+2,401
New +$229K ﹤0.01% 1168
2016
Q4 		– Sell
-3,465
Closed -$293K – 1411
2016
Q3 		$293K Sell
3,465
-16,130
-82% -$1.35M ﹤0.01% 1021
2016
Q2 		$1.59M Buy
19,595
+362
+2% +$27.6K 0.01% 513
2016
Q1 		$1.37M Buy
19,233
+158
+0.8% +$10.6K 0.01% 539
2015
Q4 		$1.36M Sell
19,075
-53
-0.3% -$3.56K 0.01% 553
2015
Q3 		$1.18M Sell
19,128
-1,794
-9% -$125K 0.01% 706
2015
Q2 		$1.52M Sell
20,922
-3,444
-14% -$254K ﹤0.01% 1443
2015
Q1 		$1.87M Sell
24,366
-1,710
-7% -$122K ﹤0.01% 1336
2014
Q4 		$1.75M Buy
26,076
+3,573
+16% +$225K ﹤0.01% 1325
2014
Q3 		$1.36M Buy
22,503
+3,030
+16% +$187K ﹤0.01% 1370
2014
Q2 		$1.14M Buy
19,473
+8,028
+70% +$470K ﹤0.01% 1408
2014
Q1 		$663K Buy
+11,445
New +$613K ﹤0.01% 1538

Other funds holding DGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Boston Partners
Boston Partners Boston, Massachusetts $95.5B AUM 28.4% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
EIG
EdgePoint Investment Group Toronto, Ontario, Canada $12.5B AUM 31.7% 1-Year Est. Return

William Blair & Company's DGX Position: Q1 2026 in Review

William Blair & Company reduced its Quest Diagnostics (DGX) stake by 11% in Q1 2026, selling an estimated $2.22M and leaving 91,972 shares worth $18M. The position accounts for 0.05% of the portfolio, ranked #257.

William Blair & Company first reported a position in DGX in Q1 2014 and has held it in 48 quarters since. The position peaked at $18.7M in Q3 2025. 1,065 funds tracked by Wall St. Rank hold DGX as of Q1 2026.

  • William Blair & Company held 91,972 shares of Quest Diagnostics worth $18M as of Q1 2026.
  • William Blair & Company sold 11,403 Quest Diagnostics shares in Q1 2026, an estimated $2.22M.
  • Quest Diagnostics made up 0.05% of William Blair & Company's portfolio in Q1 2026, its #257 holding.
  • William Blair & Company first reported a position in Quest Diagnostics in Q1 2014 and has held it in 48 quarters since.
  • William Blair & Company's Quest Diagnostics position peaked at $18.7M in Q3 2025.
  • 1,065 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2026.

Based on William Blair & Company's 13F filing for Q1 2026, filed 8 May 2026.